Provided by Tiger Fintech (Singapore) Pte. Ltd.

Fennec Pharmaceuticals Inc.

6.51
+0.38006.20%
Post-market: 6.510.00000.00%16:23 EDT
Volume:182.18K
Turnover:1.14M
Market Cap:177.67M
PE:-2.54K
High:6.64
Open:6.17
Low:5.89
Close:6.13
Loading ...

Company Profile

Company Name:
Fennec Pharmaceuticals Inc.
Exchange:
NASDAQ
Establishment Date:
1996
Employees:
29
Office Location:
68 TW Alexander Drive,PO Box 13628,Research Triangle Park,North Carolina,United States
Zip Code:
27709
Fax:
- -
Introduction:
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Directors

Name
Position
Khalid Islam
Chairman of Board, Director
Rostislav Raykov
Chief Executive Officer, Director
Adrian J. Haigh
Director
Chris A. Rallis
Director
Jodi Cook
Director
Marco Brughera
Director
Shubh Goel
Director

Shareholders

Name
Position
Rostislav Raykov
Chief Executive Officer, Director
Robert Andrade
Chief Financial Officer